Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma who are not eligible for locoregional therapy. Although significant improvement in overall survival has been demonstrated in patients with Child-Pugh A cirrhosis, information is lacking on the benefits, if any, in patients with compromised liver function and Child-Pugh B or C cirrhosis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
Journal of Translational Medicine Open Access 10 December 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646–649 (1973).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).
Kane, R. C. et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14, 95–100 (2009).
Zhu, A. X. & Clark, J. W. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist 14, 67–69 (2009).
Abou-Alfa, G. K. et al. Is sorafenib safe and effective in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis? [abstract] ASCO Meeting Abstracts. 26, a4518 (2008).
Wörns, M. A. et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 43, 489–495 (2009).
Pinter, M. et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14, 70–76 (2009).
Miller, A. A. et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol. 27, 1800–1805 (2009).
Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698–711 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. Di Maio, B. Daniele and F. Perrone declare that they are on the speakers bureau for Bayer.
Rights and permissions
About this article
Cite this article
Di Maio, M., Daniele, B. & Perrone, F. Role of sorafenib in HCC patients with compromised liver function. Nat Rev Clin Oncol 6, 505–506 (2009). https://doi.org/10.1038/nrclinonc.2009.114
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.114
This article is cited by
-
Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience
Medical Oncology (2014)
-
Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
Journal of Translational Medicine (2012)